<DOC>
	<DOCNO>NCT00868413</DOCNO>
	<brief_summary>This Phase 1 study evaluate safety ABT-263 administer combination either FCR BR subject relapse refractory chronic lymphocytic leukemia .</brief_summary>
	<brief_title>Study ABT-263 When Administered Combination With Either Fludarabine/Cyclophosphamide/Rituximab Bendamustine/Rituximab Relapsed Refractory Chronic Lymphocytic Leukemia</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Bendamustine Hydrochloride</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Navitoclax</mesh_term>
	<mesh_term>Vidarabine</mesh_term>
	<criteria>Must relapse refractory Chronic Lymphocytic Leukemia ( CLL ) , receive 5 prior myelosuppressive/chemotherapy regimen must candidate treatment either Fludarabine/Cyclophosphamide/Rituximab ( FCR ) Bendamustine/Rituximab ( BR ) ; Subject Eastern Cooperative Oncology Group ( ECOG ) performance score &lt; /=1 ; Must adequate bone marrow independent growth factor support ( exception subject bone marrow heavily infiltrate underlying disease [ 80 % ] may use growth factor support achieve Absolute Neutrophil Count ( ANC ) eligibility criterion ) , per local laboratory reference range Screening follow : ANC &gt; /=1000/mcL , Platelets &gt; /= 100,000/mm3 ( entry platelet count must independent transfusion within 14 day Screening ) , Hemoglobin &gt; /= 9.0 g/dL . Subject history clinically suspicious cancerrelated Central Nervous System disease ; Has history severe allergic anaphylactic reaction human , humanize , chimeric murine monoclonal antibody ; Has undergone allogeneic stem cell transplant ; Exhibits evidence uncontrolled condition ( ) include , limited : uncontrolled systemic infection , diagnosis fever neutropenia within 1 week prior study drug administration ; Has underlying , predispose condition bleed currently exhibit sign bleed ; Has recent history nonchemotherapy induce thrombocytopenic associate bleeding ; Currently receive require anticoagulation therapy ; Has active immune thrombocytopenic purpura ( ITP ) history refractory platelet transfusion ( within 1 year prior 1st dose study drug ) ; Has active peptic ulcer disease hemorrhagic esophagitis/gastritis .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2013</verification_date>
</DOC>